Diagnostics tests are critical for properly applying Precision Medicine in cancer care, yet they are still undervalued by payers. In a recent podcast, we had the privilege of speaking with Hannah Mamuszka, Ph.D. founder of Alva10, a company aimed at breaking the cycle of commoditization in diagnostics and bringing radically new tests to bear on value-based healthcare.

Our conversation centered around the hurdles diagnostic companies face getting technology accepted and used for patients within our health care system—one of the biggest hurdles being reimbursement.